CMO
Inflammatix
Sunnyvale, CA, United States
Oliver Liesenfeld, MD, has over 30 years of industry and academic experience in the clinical diagnostics field, with a focus on molecular diagnostics and infectious diseases. Since 2018, as Chief Medical Officer, he heads the Clinical Affairs department at Inflammatix Inc. in support of clinical trial design, clinical trial conduct and communication of medical and scientific evidence; the Clinical Affairs department supports all departments along the life cycle of product development from ideation to product marketing.
From 2008 to 2017, Oliver was Chief Medical Officer at Roche Molecular Diagnostics, where he built a state-of-the-art clinical affairs department leading the company’s clinical science, medical affairs, clinical operations and biometrics functions with ~160 staff members. His team designed and executed all clinical trials in support of regulatory approvals and trials in support of commercialization of Roche’s broad product portfolio in microbiology, virology, blood safety, women’s health, and point-of-care diagnostics.
Oliver holds an MD and a doctoral (Dr. med) degree from the Free University of Berlin and completed his residency in medical microbiology and infection epidemiology at the Charite Medical School in Berlin (including 1 year of ID training). He completed a postdoctoral fellowship in the Division of Infectious Diseases and Geographic Medicine at Stanford University from 1994-1997 (Jack Remington Lab) and was Associate Professor of Medical Microbiology and Infection Immunology at the Charite Medical School from 2001 to 2008, where his research focused on the immune response to infections and clinical diagnostics.
Oliver has authored more than 200 Pubmed-listed scientific publications and more than 30 book chapters.
I do not have any relevant financial / non-financial relationships with any proprietary interests.
Saturday, October 14, 2023
12:20 PM – 12:25 PM US ET